The intracellular pharmacology of antiretroviral protease inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 6, 2004, Pages 982-990

  Ford, J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Efflux; HIV; Influx; P glycoprotein; Pharmacokinetics

Indexed keywords

ABC TRANSPORTER; AMPRENAVIR; ANTIRETROVIRUS AGENT; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; REVIEW; TISSUE DISTRIBUTION; VIRUS REPLICATION;

DRUG MONITORING; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; P-GLYCOPROTEIN;

EID: 12344322578     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh487     Document Type: Review

References (80)

1. Robins, T. & Plattner, J. (1993). HIV protease inhibitors: their anti-HIV activity and potential role in treatment. Journal of Acquired Immune Deficiency Syndromes 6, 162-70.
2. Kuritzkes, D. R. (2003). Management of patients with virologic and metabolic failure. AIDS Reader 13, S17-S22.
3. Cinatl, J., Jr, Cinatl, J., Rabenau, H. et al. (1994). Failure of antiretroviral therapy: role of viral and cellular factors. Intervirology 37, 307-14.
4. Bilello, J. A. & Drusano, G. L. (1996). Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. Journal of Infectious Diseases 173, 1524-6.
5. Nascimbeni, M., Lamotte, C., Peytavin, G. et al. (1999). Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrobial Agents and Chemotherapy 43, 2629-34.
6. Jones, K., Hoggard, P. G., Sales, S. D. et al. (2001). Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15, 675-81.
7. Ford, J., Hoggard, P. G., Khoo, S. et al. (2003). Intracellular accumulation of protease inhibitors in subpopulations of lymphocytes with P-glycoprotein expression. British Pharmacology Society, Winter Meeting.
8. Lamotte, C., Peytavin, G., Clavel, F. et al. (2003). Subcellular distribution of HIV protease inhibitors (PI) in cell culture. In Program and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-1801. American Society for Microbiology, Washington, DC, USA.
9. Khoo, S. H., Hoggard, P. G., Williams, I. et al. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrobial Agents and Chemotherapy 46 3228-35.
10. Chaillou, S., Durant, J., Garraffo, R. et al. (2002). Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clinical Trials 3, 493-501.
11. Jones, K., Hoggard, P. G., Khoo, S. et al. (2001). Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. British Journal of Clinical Pharmacology 51, 99-102.
12. Kashuba, A. D., Dyer, J. R., Kramer, L. M. et al. (1999). Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 43, 1817-26.
13. Gao, W. Y., Cara, A., Gallo, R. C. et al. (1993). Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA, 90, 8925-8.
14. Jemal, M., Rao, S., Gatz, M. et al. (2003). Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis. Journal of Chromatography B 795, 273-89.
15. Colombo, S., Telenti, A., Guignard, N. et al. (2004). Differences in intracellular/plasma concentration ratio and intracellular drug accumulation between PIs and NNRTIs. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy, 2004. Abstract 52, p. 36. Virology Education, Utrecht, The Netherlands.
16. Ford, J., Cornforth, D., Hoggard, P. G. et al. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV infected patients; relationship with P-glycoprotein expression. Antiviral Therapy 9, 77-84.
17. van Heeswijk, R. P. G., Cohen Stuart, J. W. T., Burger, D. M. et al. (2001). Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE study. British Journal of Clinical Pharmacology 53, 211-4.
18. Ford, J., Boffito, M., Wildfire, A., et al. (2004). Intracellular and plasma pharmacokinetics (PKs) of saquinavir/ritonavir (SQV/r) administered once daily in HV infected patients. 11th Conference on Retroviruses and Opportunistic Infections, Sans Francisco, USA, 2004. Abstract 601, p. 283. Foundation for Retrovirology and Human Health, Alexandra, VA, USA.
19. Peytavin, G., Landman, R., Lamotte, C. et al. (2001). Saquinavir (SQV). plasma and intracellular concentrations in a once daily dosing combination FORTOVASE (SQV-SGC)-low dose Ritonavir (RTV) in a prospective study (IMEA 015) in HIV-infected patients (pts). 2nd International Workshop of Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, 2001. Abstract 3.16. Virology Education, Utrecht, The Netherlands.
20. Armbruster, C., Vorbach, H., Steindl, F. et al. (2001). Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells. Journal of Antimicrobial Chemotherapy 47, 487-90.
21. Hoggard, P., Meaden, E., Tjia, J., et al. (2002). The intracellular accumulation of lopinavir (LPV) and ritonavir (RTV) is influenced by the expression of efflux transporters P-glycoprotein and MRP1 in HIV infected patients receiving Kaletra. Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2002. Abstract PIL 8.2, p. 10. Gardiner-Caldwell, Tytherington, UK.
22. Breilh, D., Pellegrin, I., Rouzes, A. et al. (2004). Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study). AIDS 18, 1305-10.
23. Biedler, J. L. & Riehm, H. (1970). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Research 30 1174-84.
24. Endicott, J. A. & Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual Review of Biochemistry 58, 137-71.
25. Gottesman, M. M. & Pastan, I. (1988). The multidrug transporter, a double-edged sword. Journal of Biological Chemistry 263, 12163-6.
26. Lee, C. G., Gottesman, M. M., Cardarelli, C. O. et al. (1998). HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37, 3594-601.
27. Kim, R. B., Fromm, M. F., Wandel, C. et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation 101 289-94.
28. Chen, C. J., Chin, J. E., Ueda, K. et al. (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-9.
29. Higgins, C. F., Callaghan, R., Linton, K. J. et al. (1997). Structure of the multidrug resistance P-glycoprotein. Seminars in Cancer Biology 8, 135-42.
30. Loo, T. W. & Clarke, D. M. (1999). The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. Federation of American Societies for Experimental Biology 13, 1724-32.
31. Deeley, R. G. & Cole, S. P. (1997). Function, evolution and structure of multidrug resistance protein (MRP). Seminars in Cancer Biology 8, 193-204.
32. Litman, T., Druley, T. E., Stein, W. D. et al. (2001). From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cellular and Molecular Life Sciences 58, 931-59.
33. Gottesman, M. M., Fojo, T. & Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2, 48-58.
34. Doyle, L. A. & Ross, D. D. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-58.
35. Chan, L. M., Lowes, S. & Hirst, B. H. (2004). The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 21, 25-51.
36. Huai-Yun, H., Secrest, D. T., Mark, K. S. et al. (1998). Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochemical and Biophysical Research Communications 243, 816-20.
37. Kruh, G. D. & Belinsky, M. G. (2003). The MRP family of drug efflux pumps. Oncogene 22, 7537-52.
38. Borst, P., Evers, R., Kool, M. et al. (2000). A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 92, 1295-302.
39. Kage, K., Tsukahara, S., Sugiyama, T. et al. (2002). Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. International Journal of Cancer 97, 626-30.
40. Luckie, D. B., Wilterding, J. H., Krha, M. et al. (2003). CFTR and MDR: ABC transporters with homologous structure but divergent function. Current Genomics 4, 109-21.
41. Hoetelmans, R. M. (1998). Sanctuary sites in HIV-1 infection. Antiviral Therapy 3, Suppl. 4, 13-17.
42. Jette, L., Tetu, B. & Beliveau, R. (1993). High levels of P-glycoprotein detected in isolated brain capillaries. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1150, 147-54.
43. Neyfakh, A. A., Serpinskaya, A. S., Chervonsky, A. V. et al. (1989). Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Experimental Cell Research 185, 496-505.
44. Chaudhary, P. M., Mechetner, E. B., Roninson, I. B. et al. (1992). Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80 2735-9.
45. Wang, X., Furukawa, T., Nitanda, T. et al. (2003). Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Molecular Pharmacology 63, 65-72.
46. Mouly, S., Lown, K. S., Kornhauser, D. et al. (2002). Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clinical Pharmacology and Therapeutics 72 1-9.
47. Eagling, V. A., Profit, L. & Back, D. J. (1999). Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. British Journal of Clinical Pharmacology 48, 543-52.
48. Wacher, V. J., Silverman, J. A., Zhang, Y. et al. (1998). Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. Journal of Pharmaceutical Sciences 87, 1322-30.
49. Mouly, S. & Paine, M. F. (2003). P-glycoprotein increases from proximal to distal regions of human small intestine. Pharmaceutical Research 20, 1595-9.
50. Profit, L., Eagling, V. A. & Back, D. J. (1999). Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13, 1623-7.
51. Srinivas, R. V., Middlemas, D., Flynn, P. et al. (1998). Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrobial Agents and Chemotherapy 42, 3157-62.
52. Speck, R. R., Yu, X. F., Hildreth, J. et al. (2002). Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. Journal of Infectious Diseases 186, 332-40.
53. Owen, A., Chandler, B., Ford, J. et al. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL and CEM E1000 Cells. Journal of Infectious Diseases 187, 874-5.
54. Bleiber, G., May, M., Suarez, C. et al. (2004). MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. Journal of Infectious Diseases 189, 583-6.
55. Walker, J., Martin, C. & Callaghan, R. (2004). Inhibition of p-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. European Journal of Cancer 40, 594-605.
56. Meaden, E. R., Hoggard, P. G., Newton, P. et al. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. Journal of Antimicrobial Chemotherapy 50, 583-8.
57. Perloff, M. D., von Moltke, L. L., Fahey, J. M. et al. (2000). Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14, 1287-9.
58. Huang, L., Wring, S. A., Woolley, J. L. et al. (2001). Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metabolism and Disposition 29, 754-60.
59. Chandler, B., Almond, L., Ford, J. et al. (2003). The effect of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. Journal of Acquired Immune Deficiency Syndromes 33, 551-6.
60. Ford, J., Meaden, E. R., Hoggard, P. G. et al. (2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. Journal of Antimicrobial Chemotherapy 52, 354-8.
61. Bossi, P., Legrand, O., Faussat, A. M. et al. (2003). P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors. HIV Medicine 4, 67-71.
62. Huisman, M. T., Smit, J. W., Crommentuyn, K. M. et al. (2002). Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16, 2295-301.
63. Laupeze, B., Amiot, L., Payen, L. et al. (2001). Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sciences 68, 1323-31.
64. Gupta, A., Zhang, Y., Unadkat, J. D. et al. (2004). HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). Journal of Pharmacology and Experimental Therapeutics 310, 334-41.
65. Marzolini, C., Paus, E., Buclin, T. et al. (2004). Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 75 13-33.
66. Hoffmeyer, S., Burk, O., von Richter, O., et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences, USA 97, 3473-8.
67. Fellay, J., Marzolini, C., Meaden, E. R. et al. (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-6.
68. Johne, A., Kopke, K., Gerloff, T. et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clinical Pharmacology and Therapeutics 72, 584-94.
69. Kim, R. B., Leake, B. F., Choo, E. F. et al. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical Pharmacology and Therapeutics 70, 189-99.
70. Colombo, S., Buclin, T., Tauber, B. L., et al. (2004). Are MDR1 genotypes (3435C>T and 2677G>T) associated with total plasma and intracellular disposition of nelfinavir (NFV) and efavirenz (EFV)? 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy, 2004. Abstract 50, p. 35. Virology Education, Utrecht, The Netherlands.
71. Tanabe, M., Ieiri, I., Nagata, N. et al. (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. Journal of Pharmacology and Experimental Therapeutics 297, 1137-43.
72. Dresser, M. J., Leabman, M. K. & Giacomini, K. M. (2001). Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences 90, 397-421.
73. Lee, W. & Kim, R. B. (2004). Transporters and renal drug elimination. Annual Review of Pharmacology and Toxicology 44, 137-66.
74. Zhang, L., Gorset, W., Washington, C. B. et al. (2000). Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metabolism and Disposition 28, 329-34.
75. Su, Y., Zhang, X., Sinko, P. J. et al. (2003). Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Molecular Pharmaceutics 1, 49-56.
76. Tirona, R. G., Leake, B. F., Merino, G. et al. (2001). Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. Journal of Biological Chemistry 276, 35669-75.
77. Sweet, D. H., Bush, K. T. & Nigam, S. K. (2001). The organic anion transporter family: from physiology to ontogeny and the clinic. American Journal of Physiology - Renal Physiology 281, F197-F205.
78. Garraffo, R., Lavrut, T., Simonet, P., et al. (2004). Intracellular concentration of indinavir (IDV) in patients with AIDS receiving two different doses of indinavir/ritonavir (IDV/rtv). 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy, 2004. Abstract 82, p. 58. Virology Education, Utrecht, The Netherlands.
79. Lamotte, C., Landman, R., Peytavin, G. et al. (2004). Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antiviral Therapy 9, 247-56.
80. Hagenbuch, B., Meier, P. J. et al. (2003). The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1609, 1-18.